Pharmaceuticals company Unichem Laboratories announced Q1FY27 results Consolidated Financial Highlights: The company reported Revenue from operations of Rs 632.62 crore in Q1FY27, reflecting a YoY growth of 20.13% from Rs 526.60 crore in Q1FY26 and a QoQ increase of 10.00% from Rs 575.12 crore in Q4FY26. Other income for Q1FY27 stood at Rs 15.61 crore, compared to Rs 6.82 crore in Q1FY26 (up 128.89% YoY) and Rs 23.47 crore in Q4FY26 (down 33.49% QoQ). Total income reached Rs 648.23 crore in Q1FY27, showing a YoY increase of 21.52% from Rs 533.42 crore and a QoQ growth of 8.29% from Rs 598.59 crore. Profit before tax (PBT) for Q1FY27 was Rs 48.99 crore, compared to a loss of Rs 9.02 crore in Q1FY26 and a profit of Rs 18.79 crore in Q4FY26 (a QoQ increase of 160.72%). The company posted a Net Profit of Rs 41.47 crore in Q1FY27, as against a net loss of Rs 10.47 crore in Q1FY26 and a profit of Rs 10.91 crore in Q4FY26 (up 280.11% QoQ). Total Comprehensive Income for Q1FY27 was Rs 38.41 crore, compared to a loss of Rs 7.42 crore in Q1FY26 and a profit of Rs 20.07 crore in Q4FY26. Basic Earnings Per Share (EPS) for Q1FY27 was Rs 5.89, compared to Rs (1.49) in Q1FY26 and Rs 1.55 in Q4FY26. Standalone Financial Highlights: Revenue from operations in Q1FY27 was Rs 366.27 crore, representing a YoY decrease of 4.68% from Rs 384.25 crore in Q1FY26 and a QoQ increase of 2.82% from Rs 356.24 crore in Q4FY26. Other income for Q1FY27 was Rs 16.72 crore, compared to Rs 4.25 crore in Q1FY26 and Rs 22.22 crore in Q4FY26. Total income for Q1FY27 stood at Rs 382.99 crore, showing a YoY decline of 1.42% from Rs 388.50 crore and a QoQ growth of 1.20% from Rs 378.46 crore. Profit before tax for Q1FY27 was Rs 7.38 crore, compared to a loss of Rs 1.87 crore in Q1FY26 and a loss of Rs 10.71 crore in Q4FY26. The standalone Net Profit for Q1FY27 was Rs 5.53 crore, as against a loss of Rs 1.85 crore in Q1FY26 and a loss of Rs 15.39 crore in Q4FY26. Total Comprehensive Income for Q1FY27 was Rs 5.74 crore, compared to Rs 1.83 crore in Q1FY26 and a loss of Rs 12.74 crore in Q4FY26. Basic EPS for Q1FY27 stood at Rs 0.79, compared to Rs (0.26) in Q1FY26 and Rs (2.19) in Q4FY26. Business Highlights: Investment in Subsidiary: During the quarter ended June 30, 2026, the Company invested USD 80,000 (equivalent to Rs 0.76 crore) towards redeemable preference shares in its wholly owned subsidiary - "Unichem (China) Pvt Ltd." Labour Codes Provision: The New Labour Codes had resulted in a one-time increase in provision for employee benefits on account of recognition of past service costs of Rs 15.40 crore which was disclosed as Exceptional Items during the year ended March 31, 2026. EU Fine Settlement: The Company and its subsidiary Niche Generics Ltd. ("Niche") had received a demand order dated 17th September 2025 from the European Commission (EU) for payment of fine and interest aggregating to Euro 19.55 million and the same was fully settled by the Company on 28th October 2025. Result PDF